160 related articles for article (PubMed ID: 15737527)
1. Caspofungin as treatment for Candida glabrata hip infection.
Lejko-Zupanc T; Mozina E; Vrevc F
Int J Antimicrob Agents; 2005 Mar; 25(3):273-4. PubMed ID: 15737527
[No Abstract] [Full Text] [Related]
2. Candida glabrata endophthalmitis treated successfully with caspofungin.
Sarria JC; Bradley JC; Habash R; Mitchell KT; Kimbrough RC; Vidal AM
Clin Infect Dis; 2005 Mar; 40(5):e46-8. PubMed ID: 15714407
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin in combination with amphotericin B against Candida glabrata.
Barchiesi F; Spreghini E; Fothergill AW; Arzeni D; Greganti G; Giannini D; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2005 Jun; 49(6):2546-9. PubMed ID: 15917570
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine.
Dumaine V; Eyrolle L; Baixench MT; Paugam A; Larousserie F; Padoin C; Tod M; Salmon D
Int J Antimicrob Agents; 2008 Apr; 31(4):398-9. PubMed ID: 18242959
[No Abstract] [Full Text] [Related]
5. Successful treatment of liposomal amphotericin B refractory Candida glabrata fungaemia in a patient undergoing a stem cell transplantation.
Veldman BA; Verweij PE; Blijlevens NM
Neth J Med; 2006 Apr; 64(4):127-9. PubMed ID: 16609161
[TBL] [Abstract][Full Text] [Related]
6. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review.
Lye DC; Hughes A; O'Brien D; Athan E
Eur J Clin Microbiol Infect Dis; 2005 Nov; 24(11):753-5. PubMed ID: 16283214
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole stability in cement spacers.
Denes E; Fiorenza F; Saint-Marcoux F; Megherbi M; Dupon M; Weinbreck P
Med Mal Infect; 2012 Nov; 42(11):567-8. PubMed ID: 23044087
[No Abstract] [Full Text] [Related]
8. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
[No Abstract] [Full Text] [Related]
9. Candida inferior vena cava filter infection and septic thrombophlebitis.
Meda MS; Lopez AJ; Guyot A
Br J Radiol; 2007 Feb; 80(950):e48-9. PubMed ID: 17495055
[TBL] [Abstract][Full Text] [Related]
10. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.
Oliveira ER; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; Redding SW
Antimicrob Agents Chemother; 2005 Aug; 49(8):3544-5. PubMed ID: 16048980
[TBL] [Abstract][Full Text] [Related]
11. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
Cota J; Carden M; Graybill JR; Najvar LK; Burgess DS; Wiederhold NP
Antimicrob Agents Chemother; 2006 Nov; 50(11):3926-8. PubMed ID: 16940061
[TBL] [Abstract][Full Text] [Related]
12. Candida glabrata prosthetic hip infection.
Bartalesi F; Fallani S; Salomoni E; Marcucci M; Meli M; Pecile P; Cassetta MI; Latella L; Bartoloni A; Novelli A
Am J Orthop (Belle Mead NJ); 2012 Nov; 41(11):500-5. PubMed ID: 23431513
[TBL] [Abstract][Full Text] [Related]
13. Infectious endocarditis caused by Candida glabrata: evidence of in vivo development of echinocandin resistance.
Agnelli C; Guinea J; Valerio M; Escribano P; Bouza E; Muñoz P
Rev Esp Quimioter; 2019 Aug; 32(4):395-397. PubMed ID: 31327188
[No Abstract] [Full Text] [Related]
14. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.
Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323
[TBL] [Abstract][Full Text] [Related]
15. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
Barchiesi F; Spreghini E; Baldassarri I; Marigliano A; Arzeni D; Giannini D; Scalise G
Antimicrob Agents Chemother; 2004 Oct; 48(10):4056-8. PubMed ID: 15388480
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.
Clancy CJ; Huang H; Cheng S; Derendorf H; Nguyen MH
Antimicrob Agents Chemother; 2006 Jul; 50(7):2569-72. PubMed ID: 16801448
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.
Krogh-Madsen M; Arendrup MC; Heslet L; Knudsen JD
Clin Infect Dis; 2006 Apr; 42(7):938-44. PubMed ID: 16511756
[TBL] [Abstract][Full Text] [Related]
18. Development of candidemia on caspofungin therapy: a case report.
Cheung C; Guo Y; Gialanella P; Feldmesser M
Infection; 2006 Dec; 34(6):345-8. PubMed ID: 17180591
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole for candidosis: an important addition?
Graybill JR
Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
[No Abstract] [Full Text] [Related]
20. Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report.
Yamada SM; Tomita Y; Yamaguchi T; Matsuki T
J Med Case Rep; 2016 Nov; 10(1):316. PubMed ID: 27821139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]